BD begins first pharma-sponsored trial of wearable injector

FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE:BDX), a prominent player in the Healthcare Equipment & Supplies industry with annual revenue of $20.87 billion, announced Wednesday the commencement of the first pharmaceutical-sponsored combination product clinical trial using its BD Libertas Wearable Injector for subcutaneous delivery of complex biologics. According to InvestingPro data, the company maintains strong market presence with steady revenue growth of 5.84% over the last twelve months.

The trial follows more than 50 pre-clinical and clinical studies conducted by BD, including a device clinical study where 100% of participants indicated they would likely use the injector if prescribed. With an overall financial health score rated as "GOOD" by InvestingPro, the company demonstrates robust capacity for research and development investments.

The wearable injector is designed to potentially allow patients to self-administer medications at home rather than traveling to hospitals or clinics for infusions. The device can deliver high-viscosity biologics up to 50 centipoise and is available in 2-5 mL and 5-10 mL configurations.

"This trial demonstrates BD’s commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems, according to the company’s press release.

The biologics market is projected to grow to more than $670 billion by 2030. BD describes the injector as featuring a mechanical, patient-ready design with a "peel, stick and click" mechanism requiring no end-user filling or assembly.

BD is currently validating fill-finish and final assembly processes with multiple Contract Manufacturing Organizations to support pharmaceutical partners from development through commercial production.

The company noted that the BD Libertas Wearable Injector remains a product in development and is intended as a device component for drug-device combination products. Based on InvestingPro’s Fair Value analysis, BD currently appears undervalued, suggesting potential upside for investors interested in the company’s growth initiatives. For detailed insights and additional ProTips, investors can access the comprehensive Pro Research Report, available for BD and 1,400+ other top US stocks.

In other recent news, Becton Dickinson (BD) has announced a quarterly dividend of $1.04 per share, with an indicated annual rate of $4.16 per share. The company is also planning a strategic realignment by separating its Biosciences & Diagnostics Solutions division through a $17.5 billion merger with Waters Corporation. This transaction will result in BD receiving approximately $4 billion in cash, which it intends to use for share repurchases and debt reduction. In terms of analyst perspectives, TD Cowen has maintained its Hold rating with a $183 price target, while Stifel has reiterated a Buy rating with a $224 price target, reflecting confidence in the company’s prospects.

Additionally, BD has appointed Bilal Muhsin to lead its new Connected Care segment, focusing on integrating advanced analytics and AI with smart devices. The company’s leadership addressed a mixed fiscal second quarter of 2025, noting macroeconomic challenges that led to a sales dip and a revised organic growth forecast. Despite these challenges, BD’s management provided a positive outlook for future improvement during a recent investor meeting. These developments highlight BD’s strategic initiatives and ongoing efforts to strengthen its market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.